GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Estrogen Receptor Positive HER2- Breast Cancer
Interventions: DRUG: GS-5829|DRUG: Exemestane|DRUG: Fulvestrant
Sponsor: Gilead Sciences